Ameriprise
BIVV

Ameriprise’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Ameriprise’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-586,238
Closed -$31.6M – 3770
2017
Q4 		$31.6M Buy
586,238
+121,955
+26% +$6.67M 0.01% 794
2017
Q3 		$26.5M Buy
464,283
+138,168
+42% +$8.09M 0.01% 876
2017
Q2 		$19.6M Buy
326,115
+13,396
+4% +$763K 0.01% 1033
2017
Q1 		$17M Buy
+312,719
New +$15.4M 0.01% 1121

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Ameriprise's BIVV Position: Q1 2018 in Review

Ameriprise sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 586,238 shares — an estimated $31.6M sold.

Ameriprise first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $31.6M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Ameriprise reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Ameriprise sold 586,238 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $31.6M.
  • Ameriprise first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Ameriprise's Bioverativ Inc. Common Stock position peaked at $31.6M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Ameriprise's 13F filing for Q1 2018, filed 15 May 2018.